Prof.Dr.Halil Coşkun
8.4K posts
@drhalilcoskun
Prof. Dr. Halil Coşkun | Bariatric & Metabolic Surgeon | Longevity Medicine | GLP-1 & GIP Therapies | Epigenetic Research, Education & Innovation |@bariatriklab
Higher omega-3 levels are linked to ~15–20% lower mortality risk. More here: nature.com/articles/s4146…
Semaglutide directly targets specific liver cells to reduce inflammation and scarring, improving liver function independently of weight loss and reshaping approaches to metabolic liver disease. doi.org/hbw4cn medicalxpress.com/news/2026-04-g…
FDA new drug approvals in Q1 2026 nature.com/articles/d4157… Potential blockbusters approved in the first quarter include an oral IL-23 receptor inhibitor for psoriasis and a glucocorticoid receptor antagonist for various cancers
Aging can now be analyzed by AI 🤖 Deep learning models are identifying: • aging #biomarkers • disease risk patterns • potential #longevity therapies Aging research is becoming data + AI driven Read: pubmed.ncbi.nlm.nih.gov/39836094/ #Aging #Longevity #Healthspan #AI
What if a blood test could detect Alzheimer's before symptoms appear? 🧠 NVIDIA Inception member Prima Mente built the world's first whole-genome epigenetic AI foundation model, achieving up to 97% accuracy in early detection. 🧬 🔗 nvda.ws/4kdSFKM
📍 Ozempic etkisi: tartı düşüyor, boşanmalar artıyor
Novo Nordisk and @OpenAI partner to transform how medicines are discovered and delivered. Read more here: novonordisk.com/content/nncorp…
AI models identified patients with end-stage kidney disease (ESKD) receiving hemodialysis who faced an imminent risk for hospital admission due to infections or fluid status abnormalities. When paired with nurse-led case reviews and targeted interventions, this strategy helped avert short-term admissions, demonstrating AI’s potential to guide timely, focused care. mdsc.pe/4c7DZdV
Alzheimer’s is one of medicine's hardest unsolved problems, and one of the most devastating. At the OpenAI Foundation, we believe AI is well suited to its complexity. We're directing over $100M to scientists mapping the disease, designing drugs, & more. I wrote about it here: openaifoundation.org/news/ai-for-al…
• Çin 'AI Hastane' modelini tanımladı • TSMC geliri %35 arttı • OpenAI kurumsal strateji raporu • AGIBOT, GE-Sim 2.0'ı duyurdu • AlphaFold'a 1,7M protein eklendi • Tencent robotik modeli açık kaynak • OpenAI Vakfı Alzheimer'a 100M$ • Flexion otonom robot beyni
💬 Viewpoint: Utah authorized the first autonomous #AI drug prescriber for nearly 200 medications, bypassing physician oversight and FDA review, raising questions about safety and regulatory gaps. ja.ma/4cmPAET
When mitochondria break down, they don't just stop producing energy—they actively damage the cell. That's why mitophagy, the selective removal of broken mitochondria, may be one of the most critical processes in aging biology. This week's Research Review examines Urolithin A—a gut-derived metabolite that enhances mitophagy and restores mitochondrial quality control. When mitophagy fails, damaged organelles accumulate. The result: Parkinson's, Alzheimer's, type 2 diabetes, and muscular dystrophy all accelerate. Urolithin A restores that clearance. Emerging studies show it increases muscle strength by up to 12%, improves aerobic endurance, and lowers systemic inflammation measured by C-reactive protein. Mitochondrial function depends on two measures: ATP production and oxidative stress reduction. Urolithin A delivers both—addressing two central mechanisms of aging. gethealthspan.com/science/articl…
